Dover (NYSE: DOV) SVP exercises 39,775 stock rights and reports share sales
Rhea-AI Filing Summary
Dover Corporation senior vice president, general counsel and secretary Ivonne M. Cabrera reported multiple equity transactions in company stock. On 12/03/2025, she exercised a stock appreciation right covering 39,775 shares of common stock at an exercise price of $48.28 per share, resulting in an acquisition of the same number of Dover shares.
That same day, she disposed of 10,154 shares in an open-market sale at $189.13 per share and 13,123 shares were withheld at $189.13 to cover tax obligations. On 12/04/2025, she sold an additional 2,630 shares at a weighted average price of $190.8044 per share, with individual sale prices ranging from $190.77 to $190.895.
Following these transactions, Cabrera beneficially owned 72,968 shares of Dover common stock directly and 2,114 shares indirectly through a 401(k) plan, and no stock appreciation rights remained outstanding from this grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,630 | $190.8044 | $502K |
| Exercise | Stock appreciation right (right to acquire) | 39,775 | $0.00 | -- |
| Exercise | Common Stock | 39,775 | $48.28 | $1.92M |
| Disposition | Common Stock | 10,154 | $189.13 | $1.92M |
| Tax Withholding | Common Stock | 13,123 | $189.13 | $2.48M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- [object Object]
FAQ
What insider transactions did DOV's Ivonne M. Cabrera report on this Form 4?
Ivonne M. Cabrera, a senior vice president, general counsel and secretary of Dover Corporation (DOV), reported exercising a stock appreciation right for 39,775 shares on 12/03/2025, followed by multiple stock sales and tax-withholding transactions on 12/03/2025 and 12/04/2025.
What happened to Cabrera's stock appreciation right in Dover (DOV)?
The stock appreciation right with an exercise price of $48.28, covering 39,775 underlying shares and expiring on 02/11/2026, was fully exercised on 12/03/2025, leaving 0 derivative securities from this grant beneficially owned.